STOCKS TELEGRAPH

Tag: NASD:CVAC

  • CureVac (CVAC) Stock Surges After Favorable Patent Ruling

    CureVac (CVAC) Stock Surges After Favorable Patent Ruling

    CureVac N.V. (NASDAQ: CVAC) experienced a significant stock surge following a favorable decision in a patent dispute. The most recent market check showed that CVAC shares had increased 11.79% to $3.13. The spike comes after the European Patent Office (EPO) declared that CureVac’s European patent EP 3 708 668 B1 was still valid, although with changes to make its protections more clear.

    Opposition Dismissed, Patent Maintained

    The decision follows a hearing in which BioNTech SE’s arguments were generally rejected by the EPO’s opposition division. In April 2023, BioNTech first challenged the patent’s validity; nevertheless, the EPO’s ruling upheld its standing in a modified version.

    As CureVac continues to handle ongoing intellectual property challenges in Germany, this result represents a significant triumph. The six patents at the heart of the dispute between CVAC and BioNTech include the one that was upheld.

    Upcoming Infringement Ruling in Germany

    In light of this decision, the Düsseldorf Regional Court will have to decide whether BioNTech has violated the updated patent. The date of the infringement hearing is July 1, 2025.

    A decision in CureVac’s favor would start the process of determining possible damages. The EPO’s affirmation supports CVAC’s position that the updated patent is still enforceable and has been violated.

    The Dedication of CureVac to mRNA Innovation

    CureVac sees this court ruling as an important step in getting credit for its work on mRNA vaccine technology. The company has been at the forefront of messenger ribonucleic acid (mRNA) research, producing significant innovations such split poly-A tail technology, which enhances protein synthesis and improves vaccination efficacy.

    CureVac’s patented technology works on the basis of using customized mRNA as a data carrier to tell the body to make its own proteins that can combat a variety of ailments. CVAC remains steadfast in its determination to receive fair compensation for its innovations as it advances mRNA-based therapy in the US and European markets.

  • CureVac (CVAC): Strategic Restructuring Initiative Sparks Stock Surge

    CureVac (CVAC): Strategic Restructuring Initiative Sparks Stock Surge

    Following the announcement of a major strategic initiative, CureVac N.V. (NASDAQ: CVAC) witnessed a bullish trend in its shares on the US stock charts. The CVAC stock partially rebounded from a regular-session loss exceeding 6% by rising 4.49% in after-hours trading to $3.26.

    Focus on High-Value mRNA Projects

    In order to focus its efforts on high-value mRNA initiatives, notably in cancer and other areas with large unmet medical needs, CureVac (CVAC) has announced a significant strategic restructuring. The goal of this restructure is to create a smaller, more flexible corporation focused on technology innovation, research, and development.

    The reorganization comes after GSK and CVAC reached a new license deal worth up to €1.45 billion including royalties. As per the terms of this agreement, GSK will assume responsibility for the creation, production, and worldwide marketing of COVID-19 and influenza initiatives, including their combinations. This transition enables CureVac to concentrate on its core competencies.

    Advancements and Future Prospects

    CureVac has made notable progress in advancing its mRNA platform, demonstrated by promising Phase 2 data for influenza and COVID-19 and the recent GSK licensing agreement. The new GSK deal not only provides significant financial backing but also allows CureVac to streamline operations and emphasize technological innovation, research, and development. This change allows CVAC to better utilize mRNA technology in other areas for innovative therapeutic methods and to prioritize its cancer projects.

    CureVac anticipates reporting data from the Phase 1 study of its cancer vaccine candidate, CVGBM, in glioblastoma in the latter half of 2024. CureVac anticipates having two clinical candidates for shared-antigen cancer vaccines in solid tumors and hematological malignancies by the end of 2025, one of which will be developed in conjunction with M.D. Anderson researchers. The plan includes initiating two additional Phase 1 studies by the end of 2026.

    Financial Implications of Restructuring

    As a result of the restructuring, CureVac projects operational expenses will decrease by over 30% from 2025 onward, with personnel costs reducing by approximately €25 million. The company estimates one-time restructuring charges of around €15 million, which include employee severance, benefits, and related costs, to be incurred in the fourth quarter of 2024.